Vyvanse Cost in Nevada (2026): Cash Prices, Insurance, Medicaid, and Savings Options

What Vyvanse Actually Costs in Nevada Right Now

The gap between sticker price and what Nevadans actually pay for Vyvanse is enormous. Takeda Pharmaceuticals lists brand-name Vyvanse at roughly $390 per month for a 30-capsule supply [1]. That number rarely reflects what patients hand over at the pharmacy counter. Across Nevada retail pharmacies in 2026, the average cash-pay price with a discount coupon runs approximately $35 per month for generic lisdexamfetamine.

That $355 spread exists because generic lisdexamfetamine entered the U.S. market in August 2023 after Takeda's exclusivity expired [2]. Multiple manufacturers now produce the drug. Competition has compressed retail prices dramatically. A patient filling a 30 mg prescription at a Las Vegas or Reno chain pharmacy can typically find generic lisdexamfetamine between $25 and $50 per month using GoodRx, RxSaver, or similar aggregator tools. Brand-name Vyvanse without insurance or coupons still hovers near $390 at most Nevada pharmacies, a price that makes the generic option the clear default for uninsured patients.

Prices shift by dosage. Higher-strength capsules (50 mg, 60 mg, 70 mg) sometimes cost more, though generic pricing tends to stay relatively flat across strengths compared to the brand product [3]. Patients should confirm the exact price at their preferred pharmacy before assuming the average applies. Costco, Walmart, and independent pharmacies in Henderson, Sparks, and Carson City often price generic lisdexamfetamine lower than CVS or Walgreens locations in the same zip code.

Nevada Medicaid and Vyvanse: Not Covered

Nevada Medicaid does not cover Vyvanse on its preferred drug list. Patients enrolled in Nevada Medicaid who need a stimulant for ADHD will typically be directed toward covered alternatives like mixed amphetamine salts (generic Adderall) or methylphenidate formulations [4].

This exclusion matters. Nevada expanded Medicaid under the ACA, and roughly 900,000 residents are enrolled as of 2025 data from the Nevada Department of Health and Human Services. For those patients, the lack of Vyvanse coverage means either switching to a covered stimulant, paying cash out of pocket for lisdexamfetamine, or pursuing a prior authorization exception. Prior authorization requests for Vyvanse through Nevada Medicaid require documented failure of at least one preferred agent, per the state's clinical criteria [5]. Even with documentation, approvals are not guaranteed.

Dr. Timothy Wilens, chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "Lisdexamfetamine's prodrug mechanism offers a smoother pharmacokinetic profile than immediate-release amphetamine, which can matter for patients who experience rebound symptoms or have a history of stimulant misuse" [6]. That clinical distinction is what drives some prescribers to push for prior authorization despite the administrative burden. The 2024 American Academy of Pediatrics ADHD guideline recognizes lisdexamfetamine as a first-line option, but Nevada Medicaid's formulary committee weighs cost against incremental clinical benefit [7].

Insurance Coverage for Vyvanse Across Nevada Plans

Commercial insurance plans in Nevada vary widely in how they handle Vyvanse. Most major insurers operating in the state, including UnitedHealthcare, Anthem Blue Cross Blue Shield, Cigna, and Aetna, place brand-name Vyvanse on Tier 3 (non-preferred brand) or higher. Generic lisdexamfetamine typically lands on Tier 2.

The practical result: a patient with a Tier 2 copay structure might pay $20 to $45 per month for generic lisdexamfetamine through their plan. Brand Vyvanse on Tier 3 could run $60 to $150 per month after copay, depending on the specific plan design. High-deductible health plans common among Nevada's self-employed population and gig workers (a sizable group in Las Vegas) require patients to pay full price until meeting their deductible, which means the cash-pay generic price of ~$35 may actually beat the "insured" price early in the plan year [8].

Nevada Health Link, the state's ACA marketplace, offers plans from several carriers. Patients shopping during open enrollment should compare formulary tiers for lisdexamfetamine specifically. The plan with the lowest premium does not always offer the lowest total cost for a patient who fills a Schedule II stimulant monthly, because stimulant copays and prior authorization requirements differ by carrier.

How the Takeda Savings Card Works in Nevada

Takeda offers a manufacturer copay savings card for brand-name Vyvanse that can reduce out-of-pocket costs by up to $60 per prescription fill. The card is accepted at Nevada pharmacies. Eligibility requirements apply.

Patients must have commercial insurance to use the card. Government-insured patients (Medicaid, Medicare, Tricare, VA) are excluded by federal anti-kickback statute. The card does not apply to cash-pay transactions for the brand product. Patients using generic lisdexamfetamine are not eligible, since the card is tied to the Vyvanse brand NDC [9].

For a commercially insured Nevada patient whose Tier 3 copay for brand Vyvanse is $80, the Takeda card would bring the effective cost to $20. That makes the brand product competitive with or cheaper than the generic in some plan designs, which is precisely Takeda's intent. The savings card resets annually and has a maximum annual benefit cap, so patients should read the terms each calendar year.

Compounded Lisdexamfetamine in Nevada: Legal but Limited

Compounded lisdexamfetamine is available in Nevada through licensed 503A compounding pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and Nevada state pharmacy regulations, provided the pharmacy holds a valid NV Board of Pharmacy compounding license and dispenses pursuant to a valid patient-specific prescription [10].

A few things to understand. 503A compounding means the pharmacy prepares the medication for an individual patient based on a prescriber's order. This is distinct from 503B outsourcing facilities, which produce larger batches. Lisdexamfetamine is a Schedule II controlled substance, which adds DEA requirements to the compounding process. Not every 503A pharmacy in Nevada is willing or equipped to compound Schedule II drugs.

The cost of compounded lisdexamfetamine varies by pharmacy. Some compounding pharmacies offer prices below the generic retail price, while others charge a premium for custom dosage forms (liquid suspensions for patients who cannot swallow capsules, for example). Patients interested in this route should call compounding pharmacies directly. The Nevada State Board of Pharmacy maintains a public license lookup tool for verifying a pharmacy's compounding authorization.

One clinical consideration: compounded medications are not FDA-approved products and do not undergo the same bioequivalence testing as manufactured generics [11]. The American Society of Health-System Pharmacists' 2023 guidelines on compounding state: "Compounded preparations should be used only when a commercially available, FDA-approved product cannot meet the patient's needs" [12]. That might include allergy to a dye in the commercial capsule or a need for a dose strength not commercially manufactured.

Telehealth Prescribing of Vyvanse in Nevada

Nevada permits telehealth prescribing of Vyvanse. This is significant because lisdexamfetamine is a Schedule II controlled substance, and federal rules around telemedicine prescribing of controlled substances have changed multiple times since 2020.

The DEA's May 2023 proposed rule and subsequent 2024 interim policy allow prescribers to initiate Schedule II prescriptions via telemedicine under certain conditions [13]. Nevada's own telehealth parity law (NRS 629.515) supports audio-video telemedicine visits for prescribing, and the Nevada Board of Medical Examiners has not imposed additional restrictions beyond federal requirements for controlled substance telemedicine.

What this means practically: a patient in Elko, Pahrump, or rural Nye County can see a licensed prescriber through a telehealth platform, receive a Vyvanse diagnosis and prescription, and fill it at their local pharmacy. This expands access considerably in a state where 15 of 17 counties are classified as having mental health professional shortage areas by HRSA [14]. Wigal et al. demonstrated in a randomized controlled trial (N=314) that lisdexamfetamine significantly improved ADHD symptom scores versus placebo across all tested dose levels (30 mg, 50 mg, 70 mg; P<0.001 for each), confirming the efficacy that supports its prescription through any valid clinical encounter, including telehealth [15].

Telehealth platforms operating in Nevada (Done, Cerebral, Talkiatry, and others) typically charge $150 to $300 for an initial ADHD evaluation and $85 to $150 for follow-up visits. Those fees are separate from the medication cost.

Cheapest Ways to Get Vyvanse in Nevada: A Ranked Approach

Not every path to affordable lisdexamfetamine works for every patient. Here is how the options stack up in Nevada, ranked by typical monthly out-of-pocket cost from lowest to highest.

Generic lisdexamfetamine with a discount coupon sits at the bottom of the cost ladder. At $25 to $50 per month through GoodRx, RxSaver, or pharmacy-specific discount programs, this is the default choice for uninsured or high-deductible patients. No prior authorization, no enrollment forms.

Generic lisdexamfetamine through commercial insurance typically runs $20 to $45 per month on Tier 2. Patients with employer-sponsored coverage should check their formulary before assuming out-of-pocket pricing is cheaper.

Brand Vyvanse with the Takeda savings card plus commercial insurance can drop to $20 to $30 per month if the card's $60 discount applies fully against the copay. This only works for commercially insured patients and has annual caps.

Compounded lisdexamfetamine through a 503A pharmacy varies. Some patients pay less than the generic retail price; others pay more. This route makes the most sense when a patient has a clinical need that commercial products do not meet (specific dose, dye-free formulation, liquid form).

Brand Vyvanse at full cash price at ~$390 per month is the option of last resort and almost never necessary given generic availability.

Patients who are veterans should check the VA formulary, which does include lisdexamfetamine in many Veterans Integrated Service Networks. Tricare also covers generic lisdexamfetamine, typically at a $14 to $34 copay through the home delivery pharmacy [16].

Nevada-Specific Discount Programs and Patient Assistance

Takeda's patient assistance program, Takeda Help at Hand, provides brand-name Vyvanse at no cost to qualifying patients who are uninsured and have household income at or below 250% of the federal poverty level [17]. Nevada residents can apply directly through the program's website. Processing takes 4 to 6 weeks, and patients receive a 90-day supply shipped to their prescriber's office or home.

Nevada does not operate a state pharmaceutical assistance program comparable to New York's EPIC or Pennsylvania's PACE. However, NV Energy's low-income programs and Nevada 211 can help patients identify local nonprofits that assist with prescription costs. The Rx Outreach mail-order pharmacy offers generic lisdexamfetamine at reduced prices for patients earning below 400% FPL.

For patients aged 6 to 17, the Children's Health Insurance Program (CHIP) in Nevada, administered through Nevada Check Up, covers stimulant medications including generic lisdexamfetamine with minimal copays, typically $3 to $6 per prescription [18]. This applies even though adult Medicaid does not include Vyvanse on its preferred list.

Clinical Context: Why Lisdexamfetamine Costs What It Does

Lisdexamfetamine is a prodrug. The body converts it to dextroamphetamine after oral ingestion through enzymatic hydrolysis in red blood cells [1]. This conversion mechanism is why Takeda received patent protection and why the drug carried brand-only pricing from its 2007 FDA approval until generic entry in August 2023.

The prodrug design produces a longer, smoother duration of effect compared to immediate-release dextroamphetamine. In the key phase III trial by Wigal et al. (2017), lisdexamfetamine at doses of 30 mg, 50 mg, and 70 mg significantly reduced ADHD-RS-IV total scores compared to placebo over 4 weeks in 314 children aged 6 to 12 (effect sizes ranging from 1.28 to 1.60; P<0.001) [15]. The FDA approved Vyvanse for adult binge eating disorder in 2015 based on two trials totaling 724 patients, with the 50 mg and 70 mg doses reducing binge eating days per week from approximately 4.5 at baseline to 1.1 at 12 weeks versus 2.3 for placebo [19].

These efficacy data are clinically meaningful, but they do not change the cost calculus for most Nevada patients. Generic lisdexamfetamine is pharmacologically identical to brand Vyvanse. The FDA requires bioequivalence testing before granting generic approval, meaning the generic product delivers the same active drug, at the same rate, to the same site of action [20]. For the vast majority of patients, switching from brand to generic lisdexamfetamine produces no detectable difference in symptom control.